VVT Med Announces Acceptance of Procedure Fee for ScleroSafe® in South Korea
VANCOUVER, BC, Jan. 13, 2026 /CNW/ - VVT Med Inc. ("VVT Med" or the "Company"), a developer of innovative minimally invasive solutions for the treatment of venous disease, is pleased to announce that a procedure fee has been accepted in South Korea for treatments performed with ScleroSafe®, marking a significant milestone toward commercial market penetration.
In South Korea, acceptance of a procedure fee is a critical step that typically follows regulatory approval and reflects clinical validation and professional consensus. Completion of this process enables approved procedures to be performed under an established procedural framework within the national healthcare system.
This achievement follows a multi-year, structured market-entry process in South Korea. VVT Med executed a distribution agreement in South Korea in 2022, establishing a local commercial framework for the technology. In 2024, ScleroSafe received regulatory approval from the Korean Ministry of Food and Drug Safety ("MFDS"), enabling its clinical use in the country. In 2025, the Korean Phlebology Society issued a supportive opinion letter highlighting ScleroSafe's clinical and economic value. Following these regulatory and professional milestones, the procedure fee was accepted in December, 2025, allowing physicians to integrate the treatment into routine clinical practice.
Supporting these regulatory and clinical milestones is an already-secured distribution agreement (the "Distribution Agreement") in South Korea valued at approximately CAD 2.6 million, reflecting strong local confidence in the technology and enabling a structured commercial rollout.
"With the distribution framework in place since 2022, MFDS approval achieved in 2024, and now acceptance of a procedure fee, we have completed the key building blocks required for meaningful market entry," said Erez Tetro, CEO of VVT Med. "South Korea is a highly sophisticated medical market, and this milestone positions ScleroSafe for scalable clinical adoption."
With these elements now aligned, ScleroSafe is positioned for structured market penetration in South Korea beginning in 2026, supported by physician education initiatives, local distribution capabilities, and growing clinical awareness of non-thermal, minimally invasive venous treatments.
Omnibus Incentive Plan
Further to the Company's Annual General and Special Meeting of Shareholders ("Meeting") held on December 12, 2025, the Company's shareholders approved the adoption of an omnibus equity incentive plan (the "Omnibus Plan") for purposes of attracting, retaining and motivating key individuals. The Omnibus Plan permits such number of options (each, an "Option") to be granted equal to up to 10% of the Company's issued and outstanding common shares from time to time, together with 6,683,360 common shares of the Company available for issuance pursuant to restricted share units, deferred share units and performance share units (being 10% of the total issued and outstanding common shares of the Company when the Omnibus Plan was approved at the Meeting). The Omnibus Plan remains subject to final approval from the TSX Venture Exchange.
For the full press release, click here.
